Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.464 USD | -10.77% | +14.88% | +52.43% |
May. 15 | Brookline Capital Upgrades Dare Bioscience to Buy From Hold, Price Target is $3 | MT |
May. 14 | Transcript : Daré Bioscience, Inc., Q1 2024 Earnings Call, May 14, 2024 |
Financials (USD)
Sales 2024 * | 2.62M | Sales 2025 * | 27.84M | Capitalization | 52.57M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -10M | EV / Sales 2024 * | 20 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.89 x |
P/E ratio 2024 * |
-2.2
x | P/E ratio 2025 * |
-4.59
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.36% |
Latest transcript on Daré Bioscience, Inc.
1 day | +18.64% | ||
1 week | +26.83% | ||
Current month | +26.83% | ||
1 month | +65.82% | ||
3 months | +5.03% | ||
6 months | +79.31% | ||
Current year | +68.28% |
Managers | Title | Age | Since |
---|---|---|---|
Sabrina Johnson
FOU | Founder | 57 | 14-12-31 |
Annie Thurman
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Jessica Hatheway
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robin Steele
BRD | Director/Board Member | 68 | 14-12-31 |
Chairman | 75 | 13-12-31 | |
Sabrina Johnson
FOU | Founder | 57 | 14-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 0.471 | -9.42% | 103 747 |
24-06-07 | 0.52 | +18.64% | 810,082 |
24-06-06 | 0.4383 | +2.22% | 281,969 |
24-06-05 | 0.4288 | +0.82% | 243,816 |
24-06-04 | 0.4253 | +3.73% | 174,623 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+68.28% | 52.57M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- DARE Stock